Clinical Trial

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-25; most recent amendment 2026-04-02.
Trial Details
NCT Number NCT07269769
Lead Sponsor Tasly Pharmaceutical Group Co., Ltd
Conditions AMD
Enrollment 450 participants
Start Date 2026-04-30
Primary Completion 2031-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-08